Net Loss per Share (Tables)

3 Months Ended

12 Months Ended

Mar. 31, 2016

Dec. 31, 2015

Earnings Per Share [Abstract]

Shares Excluded From Calculation of Diluted Net Loss Per Share all Potentially Dilutive Stock Options, Preferred Stock and Warrants

	As of March 31,
	2016		2015
Stock options		4,495,704		242,893
Preferred stock		21,662,200		23,815,600
Unvested restricted stock		2,300,850		—
Warrants to purchase common stock		8,876,336		3,330,500
Total		37,335,090		27,388,993

	Years Ended December 31,
	2015		2014
Stock options		3,243,041		44,615
MabVax Series A redeemable convertible preferred stock		—		137,607
MabVax Series B redeemable convertible preferred stock		—		156,247
MabVax Series C-1 redeemable convertible preferred stock		—		412,444
Series B redeemable convertible preferred stock		—		102,895
Series A-1 preferred stock		—		742,658
Series C preferred stock		—		47,023
Series D preferred stock		19,149,100		—
Series E preferred stock		3,333,300		—
Unvested restricted stock		2,300,850		—
Warrants to purchase common stock		7,209,668		—
Total		35,235,959		1,643,489